What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

AbbVie will be releasing Phase 2 data for its experimental Cystic Fibrosis (CF) drugs that could potentially compete with Vertex's drugs. VRTX stock may move up or down, inversely related to the AbbVie data set.
mildly negative